Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 9/20 | 0.62 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.61 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.61 |
| ▸ | ITGAL | P20701 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA6 | P23280 | 2/20 | 0.58 |
| ▸ | DPP4 | P27487 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7828903 | 1.00 | PYGL (0.62) | PYGLITGB2ICAM1ITGALKDM4E | |
| SCHEMBL1124516 | 1.00 | PYGL (0.62) | PYGLITGB2ICAM1ITGALKDM4E | |
| SCHEMBL11461864 | 0.98 | PYGL (0.60) | PYGLITGB2ICAM1ITGALKDM4E | |
| SCHEMBL27560903 | 0.98 | PYGL (0.60) | PYGLITGB2ICAM1ITGALKDM4E | |
| Hydrochloric Acid SCHEMBL6821828 | 0.98 | PYGL (0.60) | PYGLITGB2ICAM1ITGALKDM4E | |
| SCHEMBL27560902 | 0.98 | PYGL (0.60) | PYGLITGB2ICAM1ITGALKDM4E | |
| SCHEMBL7622126 | 0.87 | CYP1A2 (0.54) | PYGLITGB2ICAM1ITGALHSD17B10 | |
| SCHEMBL7622123 | 0.87 | CYP1A2 (0.54) | PYGLITGB2ICAM1ITGALHSD17B10 | |
| SCHEMBL6022866 | 0.85 | KDM4E (0.70) | ITGB2ICAM1ITGALKDM4EHSD17B10 | |
| SCHEMBL2260712 | 0.85 | KDM4E (0.70) | ITGB2ICAM1ITGALKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | claimed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | claimed |
| CN-109725089-B | Gas chromatography-mass spectrometry combined method for determining three trace halogenated cinnamic acids in rice | 丁立平 | 2021-05-14 | — | — | CN | claimed |
| CN-109265458-B | Matrine-based antitumor drug compound | 中国医学科学院药用植物研究所 | 2020-09-15 | — | — | CN | claimed |
| CN-109725089-A | The gas chromatography-mass spectrometry of three kinds of halogenated cinnamic acids of trace in a kind of measurement rice | 丁立平 | 2019-05-07 | — | — | CN | claimed |
| CN-109265458-A | A kind of antineoplastic compounds based on matrine | 中国医学科学院药用植物研究所 | 2019-01-25 | — | — | CN | claimed |
| EP-1429768-B1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-11-16 | — | — | EP | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | ALOX12, ALOX15B, ALOX5 | PYGL 1385/4885ITGB2 4095/4885ICAM1 1065/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | PYGL 2663/4885ITGB2 3626/4885ICAM1 4601/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | PYGL 2267/4885ITGB2 1712/4885ICAM1 2674/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | PYGL 1969/4885ITGB2 3895/4885ICAM1 3848/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | PYGL 2300/4885ITGB2 4472/4885ICAM1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.